Clinical Trial

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL)
Protocol Amendment History 40 amendments
This ClinicalTrials.gov record has been amended 40 times since 2023-10-03; most recent amendment 2026-07-21.
Status change: Recruiting → Active, Not Recruiting 2025-11-11
Status change: Not Yet Recruiting → Recruiting 2024-01-08
Trial Details
NCT Number NCT06073821
Lead Sponsor BeOne Medicines
Conditions CLL
Enrollment 652 participants
Start Date 2023-11-11
Primary Completion 2032-02 (estimated)
Study Completion 2032-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-07